Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD5847 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| AZD5847 oral suspension | EXPERIMENTAL | Active |
| Placebo to AZD5847 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| AZD5847 | DRUG | oral suspension, 15 days |
| Placebo | DRUG | oral suspension, 15 days |
| Placebo to AZD5847 | DRUG | In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1 |
Inclusion Criteria: * BMI between 18-30 Exclusion Criteria: * Use of drugs that inhibit or induce cytochrome P450 3A4 enzymes * History of presence of gastrointestinal, hepatic or renal disease
AZD5847 is an investigational small molecule developed by AstraZeneca PLC. It has been studied in Phase 1 clinical trials in healthy adult volunteers, and its intended therapeutic indication has not been publicly disclosed. Two Phase 1 trials of AZD5847 have been completed, both conducted in the United States.
AZD5847 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored both completed Phase 1 studies of the compound, which were run in the United States in healthy adult volunteers.
AZD5847 is in Phase 1 development. Two Phase 1 trials have been completed, and no active trials are currently listed. The studies enrolled a combined total of 124 healthy volunteers, so the program remains at the earliest stage of clinical testing.
Two completed Phase 1 trials have evaluated AZD5847. NCT01116258 assessed safety and blood levels after multiple doses over 14 days in 60 healthy volunteers. NCT01037725 evaluated safety, tolerability and pharmacokinetics, including food effect, of oral doses in 64 healthy volunteers. Both were conducted in the United States.
Both AZD5847 trials were Phase 1 studies in healthy volunteers aged 18 and older, and both were randomized, double-blind and placebo-controlled. NCT01116258 enrolled 60 participants to assess safety and blood levels over 14 days of multiple dosing, while NCT01037725 enrolled 64 participants to evaluate safety, tolerability and pharmacokinetics, including food effect.
AZD5847 is not approved. It is an investigational small molecule that has completed only Phase 1 clinical testing, with two completed trials in healthy volunteers. No Phase 2 or later development has been reported for AZD5847.